Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for GBLX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2001. Start Trial.
Date Value
December 31, 2024 0.125M
September 30, 2024 0.11M
June 30, 2024 0.01M
March 31, 2024 0.247M
December 31, 2023 0.0333M
September 30, 2023 0.2524M
June 30, 2023 0.025M
March 31, 2023 0.0558M
December 31, 2022 0.017M
September 30, 2022 1.250M
June 30, 2022 0.1121M
March 31, 2022 -0.5052M
December 31, 2021 -0.0355M
September 30, 2021 0.0155M
June 30, 2021 0.0292M
March 31, 2021 1.095M
December 31, 2020 -2.730M
September 30, 2020 -0.1156M
June 30, 2020 0.2733M
March 31, 2020 0.3459M
December 31, 2019 0.6745M
September 30, 2019 1.165M
June 30, 2019 2.802M
March 31, 2019 2.817M
December 31, 2018 0.7429M
Date Value
September 30, 2018 10.50M
June 30, 2018 3.437M
March 31, 2018 7.245M
December 31, 2017 4.116M
September 30, 2017 3.032M
June 30, 2017 1.025M
March 31, 2017 5.462M
December 31, 2016 0.9868M
September 30, 2016 2.621M
June 30, 2016 1.924M
March 31, 2016 0.5703M
December 31, 2015 1.065M
September 30, 2015 0.7209M
June 30, 2015 1.622M
March 31, 2015 -0.0438M
December 31, 2014 0.0707M
September 30, 2014 0.00
June 30, 2014 3.842M
March 31, 2014 0.5347M
December 31, 2013 0.005M
September 30, 2013 0.00
June 30, 2013 0.026M
March 31, 2013 0.0035M
December 31, 2012 0.0112M
September 30, 2012 0.023M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. 0.00
CNBX Pharmaceuticals, Inc. 0.045M
Arvinas, Inc. 0.40M
Fulcrum Therapeutics, Inc. 0.356M
Definium Therapeutics, Inc. 758.70M